PIO laser SPNP: PIO Laser Sclerectomy IOP SLT Sclerectomy
Study Details
Study Description
Brief Summary
The main objective of this study is to characterize the changes in IOP over 24 hours after selective trabeculoplasty SLT (before and 1 and 6 months after treatment, decreased IOP, type of rhythm, mesor, acrophase, amplitude). The secondary objective is to evaluate changes in ocular perfusion pressure (arterial pressure - IOP) and ocular blood flow in the optic nerve head after selective laser trabeculoplasty.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Selective laser trabeculoplasty (Tango Laser, Ellex) Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA) |
Procedure: Selective Laser Trabeculoplasty (Tango Laser, Ellex)
One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
|
Outcome Measures
Primary Outcome Measures
- IOP change over 24 hours after selective trabeculoplasty SLT according to chronobiological data (decrease of IOP; type of 24h-IOP rhythm and 24h-PPm rhythm: MESOR, acrophase, bathyphase, amplitude and modeling) [Baseline and 6 months]
Secondary Outcome Measures
- Changes in the rate of ocular perfusion pressure (arterial pressure - IOP) and ocular blood flow in the optic nerve head after SLT. [Baseline and 6 months]
To find predictive factors 1 month before efficacy of the treatment (after 6 month). Efficacy is defined by a mean IOP decrease, at least 30%, with a smoothed pressure-peaks (decrease at least 40% of pressure changes) To characterize changes of ocular blood flow parameters (optic nerve head; Volume, Velocity and Flow): 20% at least of increase.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Primary Open-Angle Glaucoma
-
IOP more than 21 mmHg
-
Progression under maximal medical therapy
-
aged more than 18 years
Exclusion Criteria:
- Pregnant woman
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University Hospital of Grenoble | Grenoble | France |
Sponsors and Collaborators
- University Hospital, Grenoble
Investigators
- Principal Investigator: Jean-Paul ROMANET, Pr, University Hospital, Grenoble
Study Documents (Full-Text)
None provided.More Information
Publications
- 1012
- 2010-A00932-37